UBS Maintains Buy on Elevance Health, Raises Price Target to $523
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.
UBS analyst A.J. Rice maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $523.